









Markets
/
Stocks
/
nasdaq-ewtx
/

Edgewise Therapeutics Inc

EWTX

15.750USD

-0.300-1.87%

Close 09/29, 16:00（ET）Quotes delayed by 15 min

1.66BMarket Cap

LossP/E TTM



Edgewise Therapeutics Inc

15.750

-0.300-1.87%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Edgewise Therapeutics Inc

Currency: USD Updated: 2025-09-29

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Edgewise Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

200 / 505

Overall Ranking

338 / 4714

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

36.667

Target Price

+128.45%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Edgewise Therapeutics Inc Highlights

StrengthsRisks

Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 97.83.

Fairly Valued

The company’s latest PE is -10.14, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 106.86M shares, decreasing 3.85% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 20.29K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-29

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Edgewise Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-09-29

The company’s current valuation score is 6.62, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -10.14, which is -61.43% below the recent high of -3.91 and -141.75% above the recent low of -24.51.

Score

Industry at a Glance

Previous score

6.62

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 200/505

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-29

The company’s current earnings forecast score is 8.33, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Edgewise Therapeutics Inc is 41.50, with a high of 51.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

8.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 13 analysts

Buy

Current Rating

36.667

Target Price

+128.45%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Edgewise Therapeutics Inc

EWTX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

argenx SE

ARGX

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-29

The company’s current price momentum score is 8.85, which is higher than the Biotechnology & Medical Research industry's average of 6.76. Sideways: Currently, the stock price is trading between the resistance level at 17.27 and the support level at 13.96, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.93

Change

-0.08

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.239

Buy

RSI(14)

55.650

Neutral

STOCH(KDJ)(9,3,3)

61.548

Neutral

ATR(14)

1.027

High Vlolatility

CCI(14)

113.133

Buy

Williams %R

37.707

Buy

TRIX(12,20)

0.303

Sell

StochRSI(14)

33.230

Neutral

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

15.673

Buy

MA10

15.121

Buy

MA20

14.890

Buy

MA50

14.340

Buy

MA100

14.303

Buy

MA200

19.004

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-29

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.97. The latest institutional shareholding proportion is 101.57%, representing a quarter-over-quarter decrease of 2.55%. The largest institutional shareholder is The Vanguard, holding a total of 4.83M shares, representing 4.58% of shares outstanding, with 2.62% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

OrbiMed Advisors, LLC

15.25M

-1.71%

RA Capital Management, LP

8.91M

Baker Bros. Advisors LP

6.16M

Paradigm BioCapital Advisors LP

4.39M

-7.27%

Janus Henderson Investors

5.28M

+5.98%

BlackRock Institutional Trust Company, N.A.

5.39M

+0.59%

Novo Holdings A/S

5.35M

+7.00%

Braidwell LP

2.46M

+5.43%

The Vanguard Group, Inc.

Star Investors

4.29M

-3.87%

Perceptive Advisors LLC

6.55M

+26.78%

Risk Assessment

Currency: USD Updated: 2025-09-29

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.28. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.